Praxis Precision Medicines (PRAX) GC reports new equity awards filing
Rhea-AI Filing Summary
Praxis Precision Medicines’ General Counsel and Secretary, Alex Nemiroff, reported new equity awards and a tax-related share withholding. On January 8, 2026, he was granted 6,875 restricted stock units, each representing one share of common stock, vesting in equal annual installments over four years beginning on the one-year anniversary of the January 8, 2026 vesting start date.
On the same date, he also received a stock option for 5,500 shares at an exercise price of $294.38 per share, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. On January 10, 2026, 917 common shares were withheld at $288.45 per share to cover tax obligations from previously reported RSU vesting, leaving 26,700.667 common shares held directly and 5,500 options outstanding.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 917 | $288.45 | $265K |
| Grant/Award | Stock Option (Right to Buy) | 5,500 | $0.00 | -- |
| Grant/Award | Common Stock | 6,875 | $0.00 | -- |
Footnotes (1)
- Mr. Nemiroff was awarded 6,875 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
FAQ
What insider transactions did PRAX General Counsel Alex Nemiroff report on this Form 4?
Alex Nemiroff reported three items: a grant of 6,875 restricted stock units on January 8, 2026, a grant of a stock option for 5,500 shares at an exercise price of $294.38 on the same date, and the withholding of 917 common shares on January 10, 2026 to satisfy tax obligations from prior RSU vesting.
How do the new PRAX restricted stock units granted to Alex Nemiroff vest?
The 6,875 restricted stock units granted to Alex Nemiroff vest in equal annual installments over four years, beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. Each vested unit settles in one share of Praxis common stock.
What are the terms of Alex Nemiroff’s new PRAX stock option award?
The stock option covers 5,500 shares of Praxis common stock at an exercise price of $294.38 per share. The shares underlying the option vest over four years, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to his continued service.
What is Alex Nemiroff’s role at Praxis Precision Medicines (PRAX)?
Alex Nemiroff is an officer of Praxis Precision Medicines, serving as the company’s General Counsel and Secretary, according to the Form 4 disclosure.